| Drugs by Condition |  |
Prostate Cancer Medications
Definition of Prostate Cancer: Prostate cancer involves a malignant tumor growth within the prostate gland.
Drugs (by generic name) associated with Prostate Cancer
The following drugs and medications are in some way related to, or used in the treatment of Prostate Cancer. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Prostate Cancer Medications in the Pipeline
- November 22, 2009 - Dendreon Receives FDA Acknowledgement of Complete Response for Provenge
- November 2, 2009 - Dendreon Completes Submission of Biologics License Application for Provenge
- July 30, 2007 - D.C. Denies Prostate Cancer Vaccine, Provenge: Dendreon (WA) Not FDA To Blame
- June 1, 2007 - Prostate Cancer Patients, Survivors and Advocates Assemble on Capitol Hill to Rally against FDA's Non Approval of Provenge
- May 31, 2007 - Dendreon Announces FDA Confirms Data Required for Provenge Licensure
- May 9, 2007 - Dendreon Receives Complete Response Letter From FDA for Provenge Biologics License Application
- March 30, 2007 - Dendreon Announces FDA Advisory Committee Reviewed Provenge for Hormone Refractory Prostate Cancer
- March 27, 2007 - Dendreon to Hold Post Advisory Committee Conference Call for Provenge
- March 1, 2007 - Dendreon Announces FDA's Cellular, Tissue and Gene Therapies Advisory Committee to Review Provenge for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer
- January 16, 2007 - Dendreon’s Provenge Granted FDA Priority Review
- November 13, 2006 - Dendreon Completes Submission of Biologics License Application to FDA for Provenge in Hormone Refractory Prostate Cancer
- August 24, 2006 - Dendreon Submits Clinical and Non-Clinical Sections of Rolling BLA to FDA for Provenge
- September 14, 2005 - Dendreon Announces Plans to Submit BLA
- July 30, 2007 - GPC Biotech Withdraws Satraplatin NDA for Accelerated Approval; Plans to Resubmit With Survival Analysis
- July 25, 2007 - Oncologic Drugs Advisory Committee Recommends FDA Wait for Overall Survival Analysis of Satraplatin for Treatment of Hormone-Refractory Prostate Cancer
- May 15, 2007 - Spectrum Pharmaceuticals Announces FDA'S Oncology Drug Advisory Committee to Review Satraplatin for the Treatment of Hormone Refractory Prostate Cancer
- April 16, 2007 - FDA Accepts GPC Biotech's Satraplatin NDA for Filing and Grants Priority Review Status
- February 16, 2007 - GPC Biotech Submits NDA for Lead Oncology Drug Candidate Satraplatin
- July 12, 2006 - GPC Biotech Submits Non-Clinical Section of Rolling NDA for Satraplatin
- December 15, 2005 - GPC Biotech Begins Rolling NDA Submission for Lead Drug Candidate Satraplatin
- September 13, 2005 - FDA Advisory Committee Does Not Recommend Approval of Xinlay (atrasentan)
- February 11, 2005 - FDA Agrees to File Abbott's New Drug Application for Xinlay (Atrasentan) to Treat Metastatic Hormone-Refractory Prostate Cancer
- December 14, 2004 - Abbott Submits New Drug Application to U.S. FDA for Advanced Prostate Cancer Drug, Xinlay (atrasentan)
Latest Prostate Cancer Blog Post
Hormone Therapy Can Help Some With Prostate Cancer
MONDAY, Nov. 2 -- A brief course of hormone-blocking therapy can provide small benefits to a specific group of men who get radiation therapy for prostate cancer, a long-running study shows.
Ten-year survival was 62 percent in men with cancers graded...
View all Prostate Cancer blog posts.
Prostate Cancer Support Group Questions
Go to the Prostate Cancer support group or view all Prostate Cancer questions.
Ask a Question about Prostate Cancer:
Learn more about Prostate Cancer
Medical encyclopedia results for:
